VERA

Vera Therapeutics, Inc.

A biotechnology company developing treatments for autoimmune and kidney diseases, Vera Therapeutics makes Trutakna (atacicept), a self-administered injectable for adults with IgA nephropathy, a kidney condition driven by the immune system. It began in 2016 as Trucode Gene Repair before rebranding to Vera — Latin for "truth," echoing its motto "truth in science" — and pivoting to immunology and kidney disease. Its lead drug won U.S. approval in 2026 as a first-in-class therapy for the condition.